
Investing.com -- Medtronic (NYSE:MDT) has raised its annual revenue and earnings outlook following "broad-based, diversified" growth across several of the medical device manufacturer's businesses in its fiscal second quarter.
In a trading update, the company, which makes devices used in heart and gastrointestinal surgeries, said it now expects to deliver 2024 organic revenue growth of 4.75%, up from its prior estimate of 4.5%. Diluted adjusted earnings per share are also seen at $5.13 to $5.19, a 4 cent improvement at the midpoint from the previous guidance of $5.08 to $5.16.
Medtronic had already lifted its full-year profit projections earlier this year, citing a rebound in non-urgent operations in the wake of the COVID-19 pandemic.
"Based on the changes we've made to our operating model, incentives, and capital allocation, among other drivers, we've positioned the company to deliver consistent mid-single digit growth on the top line. As we move ahead, translating this durable revenue growth into durable earnings power remains a top priority," said Chief Financial Officer Karen Parkhill in a statement.
Shares were higher in premarket U.S. trading on Tuesday.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.